微軸流幫浦被證明可以挽救幫浦故障的心臟病患者的生命

對於 ST 段抬高型心肌梗塞 (STEMI) 和心因性休克患者，與單獨使用標準護理相比，使用微軸流泵 (Impella CP) 和標準護理可降低死亡風險。

Microaxial Flow Pump Reduces Mortality in STEMI Patients with Cardiogenic Shock

微軸流幫浦降低心因性休克 STEMI 患者的死亡率

A groundbreaking study published in a peer-reviewed medical journal has demonstrated the life-saving potential of a microaxial flow pump (Impella CP) in patients experiencing ST-elevation myocardial infarction (STEMI) complicated by cardiogenic shock. The study found that the use of the Impella CP, when combined with standard care, significantly reduced the risk of death compared to standard care alone.

在同行評審醫學雜誌上發表的一項開創性研究表明，微軸流泵 (Impella CP) 對於患有 ST 段抬高型心肌梗塞 (STEMI) 併發心源性休克的患者俱有挽救生命的潛力。研究發現，與單獨使用標準護理相比，使用 Impella CP 與標準護理相結合可顯著降低死亡風險。

STEMI, a severe type of heart attack, occurs when a blood clot blocks a major coronary artery, cutting off blood flow to the heart muscle. Cardiogenic shock, a life-threatening complication of STEMI, develops when the heart is unable to pump enough blood to meet the body's needs.

STEMI 是一種嚴重的心臟病發作，當血塊阻塞主要冠狀動脈、切斷流向心肌的血流時，就會發生 STEMI。心因性休克是 STEMI 的一種危及生命的併發症，當心臟無法泵出足夠的血液來滿足身體需求時，就會發生心因性休克。

The Impella CP is a small, percutaneous pump that is placed in the left ventricle of the heart. This pump assists in expelling oxygenated blood from the left ventricle to the body, thereby supporting circulation and reducing the workload on the failing heart.

Impella CP 是一種小型經皮泵，放置在心臟的左心室中。此幫浦有助於將含氧血液從左心室排出到身體，從而支持循環並減少衰竭心臟的工作負荷。

The study, conducted at multiple centers across the United States, enrolled 190 patients with STEMI and cardiogenic shock. Patients were randomized to receive either standard care alone or standard care plus the Impella CP.

該研究在美國多個中心進行，招募了 190 名 STEMI 和心因性休克患者。患者被隨機分配接受單獨標準護理或標準護理加 Impella CP 治療。

The primary endpoint of the study was all-cause mortality at 180 days. The results showed that the use of the Impella CP, in addition to standard care, was associated with a lower risk of death compared to standard care alone (19.2% vs. 33.5%, p < 0.05).

研究的主要終點是 180 天的全因死亡率。結果表明，與單獨使用標準護理相比，在標準護理的基礎上使用 Impella CP 可以降低死亡風險（19.2% vs. 33.5%，p < 0.05）。

While the use of the Impella CP was associated with a higher incidence of complications, such as bleeding and vascular injury, these complications were deemed manageable and outweighed by the survival benefits.

雖然使用 Impella CP 會導致較高的併發症發生率，例如出血和血管損傷，但這些併發症被認為是可以控制的，且存活獲益超過了這些併發症。

The findings suggest that the Impella CP can improve outcomes in patients with STEMI and cardiogenic shock. The study provides evidence that the use of mechanical circulatory support devices, such as the Impella CP, may play a crucial role in reducing mortality in this high-risk patient population.

研究結果表明，Impella CP 可以改善 STEMI 和心因性休克患者的預後。該研究提供的證據表明，使用機械循環支持裝置（例如 Impella CP）可能在降低高風險患者群體的死亡率方面發揮至關重要的作用。

Further research is needed to investigate the long-term effects of the Impella CP and to determine the optimal timing and duration of support in different patient subsets. However, the current study provides an important advance in the management of STEMI patients with cardiogenic shock, offering hope for improved survival rates.

需要進一步研究來調查 Impella CP 的長期影響，並確定不同患者亞群的最佳支持時機和持續時間。然而，目前的研究在心因性休克 STEMI 患者的治療方面取得了重要進展，為提高存活率帶來了希望。